Skip to Main Content

EternoGen Joins Lowell's M2D2 Incubator

Wannalancit Business Center at UMass Lowell

Lowell Sun

LOWELL -- The M2D2 incubator is adding a new name in the new year.

EternoGen Aesthetics LLC, which has products designed to restore lost dermal tissue, announced on Wednesday that it will be opening offices within the Massachusetts Medical Device Development Center (M2D2), located in the Wannalancit Mills on Lowell's Suffolk Street.

The new office will allow the company to be close to their manufacturing site in Massachusetts, and to "capitalize on the skill base that comes with the dense clustering of similar firms in the region," according to a press release announcing the new offices.

"We are pleased to welcome EternoGen to the M2D2 incubator," Stephen McCarthy, founder and director of M2D2, said in a statement. "Through the resources of UMass Lowell, the UMass Medical School and in the Massachusetts entrepreneurial ecosystem as a whole, we look forward to working with Eternogen and helping to advance their technology toward commercialization."

This year, EternoGen Aesthetics plans on launching its bio-dermal restoration product Cellifique; it's designed to produce natural-lasting aesthetic results through directly restoring dermal tissue lost with age as opposed to filling wrinkles with foreign substances.

The company worked with the Massachusetts Life Sciences Center (MLSC) on considering location options in Massachusetts to be close to their contract manufacturer, Berkshire Sterile Manufacturing (BSM) in Lee.

EternoGen plans to utilize the MLSC's Internship Challenge program to recruit local talent in line with their expansion plans.

"We are delighted to announce this critical milestone for EA as we gear up for the European launch of Cellifique in 2017," Anna Tenstam, EA's CEO, said in a statement. "Having an office close to our manufacturing site will significantly improve our operational efficiencies as we scale-up production.

"Equally, Massachusetts has one of the largest concentrations of biotech and med tech activity in the world and being a part of this will give us access to some of the leading scientific and industry talent as we expand," Tenstam added.